Eli Lilly and Company
Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products in the United States, Europe, China, Japan, and internationally. The company offers cardiometabolic health products, including Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalo…
What to know about LLY
Eli Lilly and Company is a Healthcare company with a solid overall financial profile. It scores well on size and growth, but valuation is worth keeping an eye on.
Should you consider LLY?
Based on 31 financial metrics and sector comparison. Not financial advice.
-
Eli Lilly and Company is a Healthcare company with a solid overall financial profile — it ranks in the top quarter of its Healthcare peers (1 of 59).
-
The business is both profitable and financially healthy — it keeps a good portion of what it earns and carries its debt comfortably.
-
The stock trades at a premium — investors are paying more per dollar of earnings than most S&P 500 companies. That's fine if strong growth justifies it, but leaves little room for disappointment.
-
Growth is a clear strength — revenue and earnings are expanding faster than most peers, signalling strong demand for the company's products or services.
-
This stock pays no dividend — your return depends entirely on the share price rising over time.
-
Risk is relatively low — the stock tends to be less volatile than the broader market, which typically means a smoother ride during uncertain periods.
-
Analyst sentiment is broadly positive and short interest is low — professionals who cover this stock are mostly optimistic about its near-term prospects.
-
Overall, this is a well-rounded stock with multiple genuine strengths and few obvious weaknesses. It may suit investors looking for a reliable holding in the Healthcare space.
At a glance
How it scores
We look at 31 different financial metrics and group them into categories. Here's how LLY compares to the other S&P 500 stocks.
Dive deeper — all 31 metrics 9 categories · valuation, growth, health, dividends & more Show all Hide
Valuation
Is the stock cheap or expensive relative to its earnings, sales, and assets? Lower multiples often mean better value.
| Metric | Value | vs S&P 500 |
|---|---|---|
| P/E Ratio (Trailing) | 39.00 | Below avg |
| Forward P/E | 24.69 | Below avg |
| PEG Ratio | 1.50 | Above avg |
| Price to Sales | 13.56 | Below avg |
| Price to Book | 31.46 | Below avg |
| EV/EBITDA | 28.69 | Below avg |
| Earnings Yield | 2.56% | Below avg |
Profitability
How efficiently does the company turn revenue into profit? Higher margins mean more money kept from each dollar earned.
| Metric | Value | vs S&P 500 |
|---|---|---|
| Gross Margin | 82.83% | Top 25% |
| Operating Margin | 49.39% | Top 25% |
| Net Profit Margin | 34.99% | Top 25% |
| Return on Equity | 107.46% | Top 25% |
| Return on Invested Capital | 20.74% | Top 25% |
Growth
How fast is the business expanding? Strong growth in revenue and earnings signals increasing market demand.
| Metric | Value | vs S&P 500 |
|---|---|---|
| Revenue Growth (YoY) | 55.50% | Top 25% |
| Revenue Growth (3Y CAGR) | 31.69% | Top 25% |
| EPS Growth (YoY) | 169.90% | Top 25% |
| Free Cash Flow Growth | 1340.58% | Top 25% |
Health
Can the company cover its debts and obligations? A healthy balance sheet reduces the risk of financial trouble.
| Metric | Value | vs S&P 500 |
|---|---|---|
| Current Ratio | 1.50 | Above avg |
| Debt to Equity | 1.39 | Average |
| Interest Coverage | — | N/A |
| Altman Z-Score | 8.81 | Top 25% |
Dividends
Does the company pay shareholders, and is that payment growing and sustainable?
| Metric | Value | vs S&P 500 |
|---|---|---|
| Dividend Yield | — | N/A |
| Payout Ratio | — | N/A |
| Dividend Growth (5Y) | 0.35% | Top 25% |
Cash Flow
Is real cash flowing into the business — not just accounting profits? Strong cash flow funds growth and dividends.
| Metric | Value | vs S&P 500 |
|---|---|---|
| Free Cash Flow Yield | 1.06% | Below avg |
| OCF to Sales | 28.35% | Above avg |
Risk
How volatile is the stock compared to the broader market? Lower beta and volatility mean a smoother ride.
| Metric | Value | vs S&P 500 |
|---|---|---|
| Beta (1-Year) | 0.52 | Top 25% |
| Volatility (30-Day) | 31.35% | Average |
Sentiment
What do analysts and short-sellers think? High analyst ratings and low short interest signal broad confidence.
| Metric | Value | vs S&P 500 |
|---|---|---|
| Short % of Float | 1.10% | Top 25% |
| Avg. Analyst Rating | 1.74 | Above avg |
| Target Upside % | 10.67% | Average |
Size
How large is the company by market value? Size affects stability, growth potential, and index inclusion.
| Metric | Value | vs S&P 500 |
|---|---|---|
| Market Capitalization | 979.64B | Top 25% |
How does LLY compare to…?
Pick another stock and see them side by side in seconds.
You might also look at
Companies in a similar position to LLY — based on their financial profile.